COMMUNIQUÉS West-GlobeNewswire

-
Trident Brands Subsidiary Brain Armor® Announces Nationwide Distribution With CVS Pharmacy
06/03/2019 -
Healthagen to Study Real-World Application of Welldoc’s OneTouch Reveal® Plus Among Type 2 Diabetes Patients
06/03/2019 -
Innovate Biopharmaceuticals Announces Presentation at Cowen’s 39th Annual Health Care Conference in Boston
06/03/2019 -
Tauriga Sciences Inc. Cancels its Previously Planned Corporate Action to Increase its Authorized Shares
06/03/2019 -
DLT Resolution Provides Critical Voice and Data Services to World Wide Logistics Services
06/03/2019 -
Marrone Bio Innovations to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 14th at 4:30 p.m. Eastern Time
06/03/2019 -
Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019
06/03/2019 -
Homology Medicines to Present at Cowen Healthcare Conference
06/03/2019 -
PSIQ Files Amendment # 1 to Form S-1 as the Next Step to Becoming an SEC Reporting Issuer and Uplisting to OTCQB
06/03/2019 -
Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication
06/03/2019 -
Exactus Places $1 Million Purchase Order for CBD Products to Accelerate Near Term Growth
06/03/2019 -
Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering
06/03/2019 -
SATO America Launches the New Standard in Healthcare Printing Solutions
06/03/2019 -
Genocea to Present at the Cowen & Company 39th Annual Health Care Conference
06/03/2019 -
Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
06/03/2019 -
Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
06/03/2019 -
Arise Austin Medical Center and The Hospital at Westlake Medical Center select Allscripts Sunrise
06/03/2019 -
Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update
06/03/2019 -
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
06/03/2019
Pages